Hématologie
MENUSickle cell disease and the risk of malignant haemopathies Ahead of print
Authors
1 Association Drepagreffe
2 Centre de référence de la drépanocytose
3 IMRB-Inserm U955, Bât. UITC-EFS, Créteil, France
* Correspondence
- Key words: sickle cell disease, haematological malignancies, busulfan, hydroxyurea, gene therapy, gene addition therapy, gene editing
- DOI : 10.1684/hma.2021.1703
The occurrence of haematological malignancies years after allograft rejection or gene therapy for sickle cell disease requires further delineation of the potential role of the disease and its treatments.